Press release
Cyclin Dependent Kinase Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Cyclin Dependent Kinase Inhibitor Pipeline Report to explore emerging therapies, key Cyclin Dependent Kinase Inhibitor Companies, and future Cyclin Dependent Kinase Inhibitor treatment landscapes @ Cyclin Dependent Kinase Inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cyclin Dependent Kinase Inhibitor Pipeline Report
* In January 2025:- Alliance for Clinical Trials in Oncology - This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
* DelveInsight's Cyclin Dependent Kinase Inhibitor pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Cyclin Dependent Kinase Inhibitor treatment.
* The leading Cyclin Dependent Kinase Inhibitor Companies such as Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Carrick Therapeutics, Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Reverie Labs, Aucentra Therapeutics, NiKang Therapeutics, BeiGene, AstraZeneca, Sellas Life Sciences Group , and others.
* Promising Cyclin Dependent Kinase Inhibitor Therapies such as Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
Discover how the Cyclin Dependent Kinase Inhibitor treatment paradigm is evolving. Access DelveInsight's in-depth Cyclin Dependent Kinase Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ Cyclin Dependent Kinase Inhibitor Clinical Trials and Studies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cyclin Dependent Kinase Inhibitor Emerging Drugs Profile
* Atirmociclib: Pfizer
Atirmociclib is a potential best-in-class, highly selective cyclin-dependent kinase 4 (CDK4) inhibitor currently in Phase III development by Pfizer for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). CDK4 is a protein that regulates cell division and is often overactive in certain types of breast cancer. By selectively inhibiting CDK4, atirmociclib can help slow or stop the growth of cancer cells. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Advanced or Metastatic Breast Cancer.
* BLU-222: Blueprint Medicines
BLU-222 is a highly selective and potent investigational CDK2 inhibitor with first- and best-in-class potential, designed by scientists at Blueprint Medicines. CDK2 is a cell cycle regulator and an important cancer target, with relevance in HR+/HER2- breast cancer and other malignancies, such as subsets of ovarian and endometrial cancer. Across multiple cancer types, aberrant CCNE1 hyperactivates CDK2, resulting in cell cycle dysregulation and tumor proliferation. Aberrant CCNE1 has been observed as a primary driver of disease, as well as a mechanism of resistance to CDK4/6 inhibitors. In HR+/HER2- breast cancer, the advent of CDK4/6 inhibitors has improved treatment; however, disease progression is nearly universal, and new innovation is needed to improve outcomes and prolong clinical benefit. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of HER2 negative breast cancer.
* SY-5609: Syros Pharmaceuticals
SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7), initially developed for select solid tumors. It has shown single-agent activity in various tumor types, including metastatic pancreatic cancer, characterized by prolonged stable disease and tumor shrinkage, uncommon in this refractory patient population. Combination with chemotherapy also demonstrated clinical activity, including a confirmed partial response in pancreatic cancer patients resistant to frontline therapy. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Advanced Solid Tumors.
* NKT 3447: NiKang Therapeutics
NKT-3447 is an investigational small molecule developed by NiKang Therapeutics, primarily targeting various metastatic solid tumors, including gastric cancer, ovarian cancer, and small-cell lung cancer. It functions as a selective inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a critical role in cell cycle regulation. By inhibiting CDK2, NKT-3447 aims to reduce cyclin E expression, a factor often amplified in several cancers. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Solid Tumors.
Get a detailed analysis of the latest innovations in the Cyclin Dependent Kinase Inhibitor pipeline. Explore DelveInsight's expert-driven report today! @ Cyclin Dependent Kinase Inhibitor Unmet Needs [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cyclin Dependent Kinase Inhibitor Companies
Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Carrick Therapeutics, Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Reverie Labs, Aucentra Therapeutics, NiKang Therapeutics, BeiGene, AstraZeneca, Sellas Life Sciences Group and others.
Cyclin Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Cyclin Dependent Kinase Inhibitor Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming Cyclin Dependent Kinase Inhibitor Therapies and key Cyclin Dependent Kinase Inhibitor Developments @ Cyclin Dependent Kinase Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cyclin Dependent Kinase Inhibitor Pipeline Report
* Coverage- Global
* Cyclin Dependent Kinase Inhibitor Companies- Syros Pharmaceuticals, Exelixis, Prelude Therapeutics, Blueprint Medicines, Vincerx Pharma, Carrick Therapeutics, Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Reverie Labs, Aucentra Therapeutics, NiKang Therapeutics, BeiGene, AstraZeneca, Sellas Life Sciences Group, and others.
* Cyclin Dependent Kinase Inhibitor Therapies- Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
* Cyclin Dependent Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cyclin Dependent Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Cyclin Dependent Kinase Inhibitor drug development? Find out in DelveInsight's exclusive Cyclin Dependent Kinase Inhibitor Pipeline Report-access it now! @ Cyclin Dependent Kinase Inhibitor Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Cyclin-Dependent Kinase Inhibitor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cyclin-Dependent Kinase Inhibitor - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atirmociclib: Pfizer
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Early Stage Products (Phase I)
* SY-5609: Syros Pharmaceuticals
* Preclinical Stage Products
* Drug Name: Company Name
* Inactive Products
* Cyclin-Dependent Kinase Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding
* Cyclin-Dependent Kinase Inhibitor - Unmet Needs
* Cyclin-Dependent Kinase Inhibitor - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cyclin-dependent-kinase-inhibitor-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
Legal Disclaimer:Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cyclin Dependent Kinase Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3860101 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Cyclin
Cyclin Dependent Kinase (CDK) Inhibitors Market - Current Impact to Make Big Cha …
The Cyclin Dependent Kinase (CDK) Inhibitors Market was valued at approximately USD 6.7 billion in 2023 and is projected to reach around USD 13.1 billion by 2033, growing at an estimated CAGR of 6.5% from 2024 to 2033.
Cyclin Dependent Kinase (CDK) Inhibitors Market Overview
The Cyclin Dependent Kinase (CDK) Inhibitors Market is witnessing steady growth driven by the increasing prevalence of various cancers, particularly breast cancer, and the rising demand for…
Surging Prevalence Of Breast Cancer Fuels Expansion In The Cyclin-Dependent Kina …
The Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Market Size and Its Estimated Growth Rate?
The market for cyclin-dependent kinase (CDK) 4/6 inhibitor drugs has seen a significant surge…
Cyclin-Dependent Kinase Inhibitor Market Poised for Breakthrough Growth: Innovat …
The global Cyclin-Dependent Kinase (CDK) inhibitor market is entering an exciting chapter of expansion and innovation, driven by breakthroughs in cancer biology, an increasing pipeline of next-generation molecules, and strong commercial uptake of approved therapies. CDK inhibitors have emerged as a transformative class of targeted anticancer agents, disrupting key cell-cycle checkpoints that tumors rely on for uncontrolled proliferation. As precision oncology advances, the demand for CDK inhibitors is set to…
Cyclin Dependent Kinase 9 Market Growth Expected to See Next Level: Astex Pharma …
The Latest published market study on Cyclin Dependent Kinase 9 Market provides an overview of the current market dynamics in the Cyclin Dependent Kinase 9 space, as well as what our survey respondents- all outsourcing decision-makers- predict the market will look like in 2029. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify gaps and opportunities.…
Cyclin Dependent Kinase Market Will Generate Record Revenue by 2029
Cyclin dependent kinase market is anticipated to grow at a significant CAGR during the forecast period. Cyclin-dependent kinases (CDKs) are protein kinases that are categorized by requiring a separate subunit, a cyclin. They provide domains essential for enzymatic activity and plays an important role in the control of cell division. Additionally, they modulate transcription in response to several extra- and intracellular cues. The major factor driving the growth of the…
Cyclin Dependent Kinase Market to Signify Strong Growth by 2023-2029
Cyclin dependent kinase market is anticipated to grow at a significant CAGR during the forecast period (2023-2029). Cyclin-dependent kinases (CDKs) are protein kinases that are categorized by requiring a separate subunit, a cyclin. They provide domains essential for enzymatic activity and plays an important role in the control of cell division. Additionally, they modulate transcription in response to several extra- and intracellular cues. The major factor driving the growth of…
